AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs AMAP 102 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 01 Jun 2010 Positive results reported in an AnaMar media release.
- 01 Jun 2010 Status changed from discontinued to completed according to an AnaMar media release.